JP7808029B2 - 心血管石灰化の治療、進行の抑制、または予防における使用のためのイノシトールリン酸化合物 - Google Patents

心血管石灰化の治療、進行の抑制、または予防における使用のためのイノシトールリン酸化合物

Info

Publication number
JP7808029B2
JP7808029B2 JP2022516283A JP2022516283A JP7808029B2 JP 7808029 B2 JP7808029 B2 JP 7808029B2 JP 2022516283 A JP2022516283 A JP 2022516283A JP 2022516283 A JP2022516283 A JP 2022516283A JP 7808029 B2 JP7808029 B2 JP 7808029B2
Authority
JP
Japan
Prior art keywords
calcification
pharmaceutical composition
weeks
inositol
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022516283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500020A (ja
JP2023500020A5 (cg-RX-API-DMAC10.html
Inventor
ベスタルド，フアン ペレロ
ロカ，カロリーナ サルセド
レイネス，ミゲル・ダビド フェレール
Original Assignee
ビフォー （インターナショナル） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビフォー （インターナショナル） リミテッド filed Critical ビフォー （インターナショナル） リミテッド
Publication of JP2023500020A publication Critical patent/JP2023500020A/ja
Publication of JP2023500020A5 publication Critical patent/JP2023500020A5/ja
Application granted granted Critical
Publication of JP7808029B2 publication Critical patent/JP7808029B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/177—Esters of thiophosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022516283A 2019-11-11 2020-11-10 心血管石灰化の治療、進行の抑制、または予防における使用のためのイノシトールリン酸化合物 Active JP7808029B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382990.0 2019-11-11
EP19382990.0A EP3818983A1 (en) 2019-11-11 2019-11-11 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
PCT/EP2020/081674 WO2021094331A1 (en) 2019-11-11 2020-11-10 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification

Publications (3)

Publication Number Publication Date
JP2023500020A JP2023500020A (ja) 2023-01-04
JP2023500020A5 JP2023500020A5 (cg-RX-API-DMAC10.html) 2023-10-26
JP7808029B2 true JP7808029B2 (ja) 2026-01-28

Family

ID=68610132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516283A Active JP7808029B2 (ja) 2019-11-11 2020-11-10 心血管石灰化の治療、進行の抑制、または予防における使用のためのイノシトールリン酸化合物

Country Status (10)

Country Link
US (2) US20220339171A1 (cg-RX-API-DMAC10.html)
EP (2) EP3818983A1 (cg-RX-API-DMAC10.html)
JP (1) JP7808029B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220099957A (cg-RX-API-DMAC10.html)
CN (2) CN114585367A (cg-RX-API-DMAC10.html)
AU (1) AU2020381775B2 (cg-RX-API-DMAC10.html)
CA (1) CA3156023A1 (cg-RX-API-DMAC10.html)
IL (1) IL292118B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022004971A (cg-RX-API-DMAC10.html)
WO (1) WO2021094331A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021003653A (es) 2018-10-11 2021-06-23 Sanifit Therapeutics S A Inositol fosfatos para el tratamiento de calcificacion ectopica.
CN113712976B (zh) * 2021-10-21 2023-02-24 中国人民解放军海军军医大学 小分子化合物肌醇六磷酸酯钠水合物在制备抗SARS-CoV-2药物中的应用
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs
US20250217970A1 (en) * 2023-12-28 2025-07-03 Case Western Reserve University Risk prediction of heart failure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271915A1 (en) 2013-03-15 2014-09-18 Laboratoris Sanifit, S.L. Use of derivatives containing c-o-p bonds in patients with kidney failure
JP2016514119A (ja) 2013-03-15 2016-05-19 ラボラトリス サニフィット，エセ．エレ． 腎不全を患っている患者におけるｃ−ｏ−ｐ結合を含む誘導体の使用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
MX347723B (es) 2011-09-29 2017-05-10 Eth Zuerich Compuestos farmaceuticos para usarse en la terapia de infeccion por clostridium difficile.
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
SMT202100406T1 (it) 2015-12-11 2021-09-14 Eth Zuerich Derivati di inositolo per l'uso nella cristallizzazione patologica
ES2762984T3 (es) 2015-12-11 2020-05-26 Eth Zuerich 4,6-di-(O-tiofosfato)-inositol-1,2,3,5-tetra-O-sulfato para la infección por C. difficile

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271915A1 (en) 2013-03-15 2014-09-18 Laboratoris Sanifit, S.L. Use of derivatives containing c-o-p bonds in patients with kidney failure
JP2016514119A (ja) 2013-03-15 2016-05-19 ラボラトリス サニフィット，エセ．エレ． 腎不全を患っている患者におけるｃ−ｏ−ｐ結合を含む誘導体の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
British Journal of Clinical Pharmacology，2018年，Vol.84，p.2867-2876
Journal of Nephrology，2019年08月10日，Vol.32，p.811-821

Also Published As

Publication number Publication date
IL292118B2 (en) 2026-08-01
CA3156023A1 (en) 2021-05-20
EP3818983A1 (en) 2021-05-12
CN114585367A (zh) 2022-06-03
AU2020381775B2 (en) 2026-03-26
KR20220099957A (ko) 2022-07-14
US20250295676A1 (en) 2025-09-25
JP2023500020A (ja) 2023-01-04
US20220339171A1 (en) 2022-10-27
AU2020381775A1 (en) 2022-04-14
CN122080055A (zh) 2026-05-26
IL292118B1 (en) 2026-04-01
MX2022004971A (es) 2022-06-08
IL292118A (en) 2022-06-01
WO2021094331A1 (en) 2021-05-20
EP4058030A1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
US20250295676A1 (en) Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
JP6863618B2 (ja) 腎不全を患っている患者におけるｃ−ｏ−ｐ結合を含む誘導体の使用
US20240066042A1 (en) Use of derivatives containing c-o-p bonds in patients with kidney failure
JP2024175025A (ja) 組織の灌流の増加における使用のためのイノシトールリン酸化合物
US20250302853A1 (en) Ip and ip analogs dosage regimens for the treatment of ectopic calcifications
WO2016203468A1 (en) Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
RU2832087C1 (ru) Соединения инозитолфосфата для применения в лечении, замедлении прогрессирования или предупреждении сердечно-сосудистой кальцификации
HK40066584A (en) Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
JP5485704B2 (ja) 骨吸収と骨形成の不均衡を是正するための方法ならびにキット及び組成物
HK40051461A (en) Inositol phosphate compounds for use in increasing tissular perfusion
HK40061817A (en) Use of derivatives with c-o-p bonds in patients with renal failure
BR112021006004B1 (pt) Uso de inositol hexafosfato

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250925

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260116

R150 Certificate of patent or registration of utility model

Ref document number: 7808029

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150